Loading
A phase 3 trial testing Cetrelimab in bladder & urothelial cancer, active and no longer recruiting.
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) is a phase 3 interventional study registered as NCT05714202, led by Janssen Research & Development, and active but no longer recruiting on the registry. Official title: A Phase 3, Open-Label, Multi-Center, Randomised Study Evaluating the Efficacy and Safety of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer. Planned enrolment is 1135 participants (actual). The study started in 2023-03-23 and primary completion is expected in 2029-09-18. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cetrelimab, Johnson & Johnson, Bladder & urothelial cancer.
Shares Cetrelimab, Johnson & Johnson.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Johnson & Johnson, Bladder & urothelial cancer.
Shares Cetrelimab, Johnson & Johnson.
Shares Cetrelimab, Johnson & Johnson, Bladder & urothelial cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/